Description Pharmacological effects Pharmacokinetics synthetic route Indications Dosage side effects Safety Side effects Chemical Properties Uses
ChemicalBook > CAS DataBase List > Rebamipide

Rebamipide

Description Pharmacological effects Pharmacokinetics synthetic route Indications Dosage side effects Safety Side effects Chemical Properties Uses
Product Name
Rebamipide
CAS No.
90098-04-7
Chemical Name
Rebamipide
Synonyms
Mucosta;Rebagen;NSC1538;Rui pat;opc12759;NSC 1538;NSC-1538;0PC-12759;opc-12759;Rebamipid
CBNumber
CB5700987
Molecular Formula
C19H15ClN2O4
Formula Weight
370.79
MOL File
90098-04-7.mol
More
Less

Rebamipide Property

Melting point:
288-290°C dec.
Boiling point:
695.0±55.0 °C(Predicted)
Density 
1.394±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,Room Temperature
solubility 
DMSO: >5mg/mL
pka
3.38±0.10(Predicted)
form 
powder
color 
white
Merck 
14,8124
InChIKey
ALLWOAVDORUJLA-UHFFFAOYSA-N
CAS DataBase Reference
90098-04-7(CAS DataBase Reference)
More
Less

Safety

RIDADR 
UN 2811 6.1 / PGIII
WGK Germany 
3
RTECS 
VC2518500
HS Code 
29337900
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H301Toxic if swalloed

Precautionary statements

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
R5655
Product name
Rebamipide hydrate
Purity
≥98% (HPLC), powder
Packaging
5mg
Price
$82.8
Updated
2024/03/01
Sigma-Aldrich
Product number
R5655
Product name
Rebamipide hydrate
Purity
≥98% (HPLC), powder
Packaging
25mg
Price
$332
Updated
2024/03/01
TCI Chemical
Product number
R0085
Product name
Rebamipide
Purity
>98.0%(HPLC)
Packaging
1g
Price
$17
Updated
2024/03/01
TCI Chemical
Product number
R0085
Product name
Rebamipide
Purity
>98.0%(HPLC)
Packaging
5g
Price
$47
Updated
2024/03/01
Cayman Chemical
Product number
17186
Product name
Rebamipide
Purity
≥98%
Packaging
1g
Price
$62
Updated
2024/03/01
More
Less

Rebamipide Chemical Properties,Usage,Production

Description

Rebamipide is a quinolinone derivative that stimulates endogenous PGE2 generation in gastric mucosa, enhancing gastric mucosal defense in a COX-2-dependent manner.
Rebamipide has been shown to inhibit the production of reactive oxygen species and to decrease cytokine release induced by H. pylori infection.
A daily oral dose of 100 mg/kg was found to be protective against the development of pyloric channel ulcers in Mongolian gerbils infected with H. pylori.
In addition to the stomach, rebamipide can also enhance secretion of mucin covering the conjunctiva and cornea, which is important for tear film adhesion.
Rebamipide, a gastroprotective drug, was developed in Japan and was proven to be superior to cetraxate, the former most prescribed drug of the same category, in 1989 in the treatment for gastric ulcers. The initially discovered basic mechanisms of action of rebamipide included its action as a prostaglandin inducer and oxygen free-radical scavenger. In the last 5 years, several basic and clinical studies have been performed for functional dyspepsia, chronic gastritis, NSAID-induced gastrointestinal injuries, gastric ulcer following eradication therapy for Helicobacter pylori, gastric ulcer after endoscopic surgery and ulcerative colitis. In addition, several molecules have been identified as therapeutic targets of rebamipide to explain its pleiotropic pharmacological actions.

Pharmacological effects

The chemical structure of rebamipide contains the para-amide groups in the benzyl group, the carbonyl group in 2’ position, and the double bond in 3’, 4’ position. It has a dose-dependent inhibitory effect on the reactive oxygen species produced by the activation of neutrophils and can further effectively scavenger free radicals, thereby preventing the damage of free radical on the gastric mucosa. This product can also promote gastric prostaglandin synthesis, enhance gastric mucosal barrier. In addition, by preventing the adhesion of Helicobacter pylori (Hp) adhesion to gastric epithelial cells, the product can reduce oxidative stress, reduce the concentration of cell factor produced by H. pylori and further inhibiting of HP’s injury on gastric mucosa.
Animal experiment has already showed that rebamipide can remove free radicals within the epithelial cells, and have a significant inhibition on the O2-produced by neutrophils; it also has some effects on eliminating hydroxyl radical; it can also inhibit HP and its production of chemotaxis factors. It can also inhibit the injury of gastric mucosa caused by bile acid and increase the synthesis of prostaglandins.
The above information is edited by the chemicalbook of Dai Xiongfeng.

Pharmacokinetics

Absorption and Metabolism: After oral administration of 0.6g, the time for reaching peak of plasma concentration is (1.95 ± 0.73) h, the peak plasma concentration is (510.3 ± 152.0) ng/ml, its elimination half-life is (1.75 ± 0.63) hours. According to reports, after oral administration of 0.1 g of rebamipide 0.1g, after about two hours, the plasma concentration reaches peak at 210ng/ml with the elimination half-life of about 2 hours; about 10% of the dose is excreted through the urine. Multiple dose study has showed that the drug did not accumulate in the human body.

synthetic route


Figure 2 The synthetic route of Rebamipide.

Indications

1. Prevents and treatment of injury of gastric mucosal caused by NSAIDs
Rebamipide has an obvious reversal effect on the side effects of NSAIDs drug-induced reduction of the synthesis of gastric mucosal prostaglandin and increased permeability of mucosa. Further study has found that patients taking NSAIDs had gotten high expression of gastric epithelial HIF-1, suggesting that the gastric mucosa of patients is within hypoxic-ischemic state; However, patients taking rebamipide has significantly reduced HIF-1 expression, demonstrating that rebamipide has a very good protective effect on the gastric mucosa of patients taking NSAIDs table. From this perspective, rebamipide may have a prevention and treatment effect on NSAIDs (especially non-selective NSAIDs) induced gastric mucosal damage.
2. HP-related gastritis treatment
Haruma et al have reported that: in the observation of clinical treatment of 86 HP-positive patients, 53 patients taking rebamipide had stomach antrum and stomach body monocytes with significant reduction on granulocytes cell infiltration and had the stomach inflammation much more be alleviated than those without medication, indicating that it has a high-quality effect on treating HP-associated gastritis.
3. Other
Studies have reported that patients with gastric cancer who have taken rebamipide before surgeries had significant lower body temperature than the control group at 3 days after surgeries. Moreover, their serum IL-6 levels are also significantly lower than the control group, demonstrating that rebamipide has alleviated effect on the post-surgery systemic inflammatory response syndrome of gastric cancer patients; rebamipide may also become a new means of treatment for ulcerative colitis; may also become a new and effective approach for treating Meniere's disease.

Dosage

The adult dosage of rebamipide is 100 mg orally three times daily.
RAU: 3 tablets/day for 7-14 days.
Behcet's disease: 3 tablets/day for 2 months.

side effects

The most commonly reported Rebamipide side effects:
   Pyrexia (4)
   Pleural Effusion (4)
   Renal Failure Acute (4)
   Liver Disorder (4)
   Nausea (4)
   Pancytopenia (3)
   Dyspnoea (3)
   Diarrhoea (3)
   Hypokalaemia (3)
   Malaise (3)
   Renal Impairment (3)
   Decreased Appetite (3)
   Transitional Cell Carcinoma (2)
   Constipation (2)
   Urticaria (2)
   Pruritus (2)
   Vomiting (2)
   Feeling Abnormal (2)
   Blood Glucose Increased (2)
   Blood Pressure Decreased (2)
Hypersensitivity and rash was seen in less than 1% of patients.

Safety

Rebamipide promotes the ulcer healing rate to be as high as 56% to 67%, higher than other gastric mucosal protective agent; it can increase the eradication frequency without the increase of antibiotics, preventing phenomenon of the increase of adverse reactions caused by increased dose of antibiotics.

Side effects

Adverse reactions include leukopenia, thrombocytopenia, dizziness, drowsiness, numbness, abnormal taste, bloating, constipation, thirst, nausea, vomiting, heartburn, belching, abdominal pain, diarrhea, throat foreign body sensation, increased blood urea nitrogen, swollen breasts galactorrhea, menstrual disorders and eczema. It may also cause male breast enlargement. It can also occasionally cause coughing, difficulty in breathing, palpitations, fever, swelling, rash, itching and liver dysfunction. During the medication, if allergic reactions such as itching, rashes or eczema occurs, stop taking drugs immediately. The incidence is about 2.2% with the symptoms disappearing after withdrawal. Disable it for people who are allergic to this drug. The elderly and pregnant women should take with caution. Lactating women should stop breastfeeding upon medication. Safety of children's medication safety is still unclear.

Chemical Properties

obtain the white powder from dimethylformamide-water with its hemihydrate m.p. being 288-290°C (decomposition).
(-)-Configuration: from dimethylformamide to give colorless needles, mp 305~306 °C (decomposition). [α] D20-116.7 ° (C = 1.0, dimethylformamide).
(+)-Configuration: from dimethylformamide to give colorless needles, mp 305~306 °C (decomposition). [α] D20 + 116.9 ° (C = 1.0, dimethylformamide).

Uses

It is used for treating stomach ulcers.
It is a kind of novel anti-ulcer drugs.

Chemical Properties

White Powder

Uses

Shows antiulcer activity in rats

Uses

antiulcer, antioxidant

Uses

An inducer of endogenous prostaglandin and a oxygen-derived free radical scavenger.

Definition

ChEBI: 2-[[(4-chlorophenyl)-oxomethyl]amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid is a secondary carboxamide.

Biochem/physiol Actions

Rebamipide is an anti-ulcer agent with free-radical scavenging and anti-inflammatory effects. It has been used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating COX-2 genes. Rebamipide significantly reduced ulcerogenesis and maintained mucosal superoxide dismutase (SOD) activity. It has also been used for the treatment of Beh?et′s disease. Rebamipide may be involved in a noval mechanism to enhance tear secretion and increase mucin levels covering conjunctiva and cornea.

Rebamipide Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Rebamipide Suppliers

Jiangxi Synergy Pharmaceutical Co. Ltd.
Tel
021-62886322 15901640172
Email
info@jxsynergy.com
Country
China
ProdList
8
Advantage
58
Hubei Zhongshan Medical Technology Co., Ltd
Tel
027-61907345 13397111514
Fax
3443707954
Email
w13397111514@163.com
Country
China
ProdList
1008
Advantage
58
Suzhou Huaxin Pharmaceutical Technology Co., Ltd.
Tel
0512-67260010 13773004275
Email
vic.xu@hx-pharma.com
Country
China
ProdList
19
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
4006608290; 18621169109
Fax
86-21-61259102
Email
market03@meryer.com
Country
China
ProdList
40241
Advantage
62
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Fax
021-67121385
Email
Sales-CN@TCIchemicals.com
Country
China
ProdList
24539
Advantage
81
Energy Chemical
Tel
021-021-58432009 400-005-6266
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
44853
Advantage
61
Wuhan Chemwish Technology Co., Ltd
Tel
86-027-67849912
Fax
86-027-87531808
Email
sales@chemwish.com
Country
China
ProdList
35906
Advantage
56
Pure Chemistry Scientific Inc.
Tel
001-857-928-2050 or 1-888-588-9418
Fax
001-617-206-9595
Email
sales@chemreagents.com
Country
United States
ProdList
10194
Advantage
62
Adamas Reagent, Ltd.
Tel
400-6009262 16621234537
Fax
021-64823266
Email
zhangsn@titansci.com
Country
China
ProdList
14113
Advantage
59
More
Less

View Lastest Price from Rebamipide manufacturers

Sinoway Industrial co., ltd.
Product
Rebamipide 90098-04-7
Price
US $0.00/Kg/Bag
Min. Order
2Kg/Bag
Purity
99% up / USP/JP/GMP/DMF
Supply Ability
20 tons
Release date
2021-07-21
Shaanxi Dideu Medichem Co. Ltd
Product
Rebamipide 90098-04-7
Price
US $1.00-1.00/Kg/Bag
Min. Order
1g
Purity
99%
Supply Ability
50tons
Release date
2020-04-30
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Rebamipide 90098-04-7
Price
US $0.00/Kg/Bag
Min. Order
1KG
Purity
99%min
Supply Ability
5000kg
Release date
2021-09-09

90098-04-7, RebamipideRelated Search:


  • (+-)-1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoica
  • (+-)-2-(4-chlorobenzoylamino)-3-(2(1h)-quinolinon-4-yl)propionicacid
  • Mucosta
  • Proamipide
  • 2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo- (+-)-4-quinolinepropanoic acid
  • 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid
  • 2-(4-CHLOROBENZAMIDO)-3-(2-OXO-1,2-DIHYDROQUINOLIN-4-YL)PROPANOIC ACID
  • OPC-12759, Mucosta, α-[(4-Chlorobenzoyl)-amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic Acid
  • 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-
  • (+-)-1,2-Dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoic acid
  • 4-Quinolinepropanoic acid, 1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-, (+-)
  • 2-(4-Chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propionic acid
  • α-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic acid
  • 2-[(4-chlorobenzoyl)amino]-3-(2-keto-1H-quinolin-4-yl)propionic acid
  • 2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
  • 2-[(4-chlorophenyl)carbonylamino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
  • Korea-FDA API
  • 2-(4-Chlorobenzamido)-3-[2(1H)-quinolinon-4-yl]propionic Acid
  • Mucosta hydrate
  • α-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepmpanoic acid
  • 0PC-12759
  • (111911-87-6) rebamipide
  • REBAMIPIDE
  • REBAPIMIDE
  • REBAMIPIDE,99.5%
  • RebamipideRebamipide
  • 4-Quinolinepropanoic acid, a-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- (9CI)
  • OPC 12759 hydrate
  • Proamipide hydrate
  • Rebamipide hydrate
  • α-[(4-Chlorobenzoyl)amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic acid hydrate
  • OPC-12759, Mucosta, a-[(4-Chlorobenzoyl)-amino]-1,2-dihydro-2-oxo-4-quinolinepropanoic Acid
  • Rebagen
  • Rebamipide, 99%, Inducer of endogenous prostaglandin and a oxygen-derived free radical scavenger
  • 1,2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-4-quinolinepropanoicaci(
  • 2-dihydro-alpha-((4-chlorobenzoyl)amino)-2-oxo-(+-)-4-quinolinepropanoicaci
  • opc12759
  • opc-12759
  • Rebamipid
  • Rebamipide &gt
  • 4-Quinolinepropanoic acid, α-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo-
  • hot selling Rebamipide
  • 2-(4-Chlorobenzamido)-3-(2-oxo-1,2-dihydro-4-quinolyl)propanoic Acid
  • RebamipideQ: What is Rebamipide Q: What is the CAS Number of Rebamipide Q: What is the storage condition of Rebamipide
  • Rebamipide 98% (HPLC)
  • NSC 1538
  • NSC1538
  • NSC-1538
  • Rui pat
  • 4-Quinolinepropanoic acid, α-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo-
  • Ruibapaite Impurity 3
  • 2-(4-Dhlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid
  • α-[(4-Chlorobenzoyl)Amino]-1,2-Dihydro-2-Oxo-4-Quinolinepropanoic Acid
  • Rebamipide impurities
  • Rebapaite
  • 90098-04-7
  • 90089-04-7
  • 11911-90-1